Janney Montgomery Scott LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 0.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 123,614 shares of the medical instruments supplier’s stock after acquiring an additional 472 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Becton, Dickinson and Company were worth $29,804,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the business. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the third quarter worth $26,000. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth $45,000. Abound Wealth Management grew its position in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC grew its position in Becton, Dickinson and Company by 1,233.3% in the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Becton, Dickinson and Company Price Performance
BDX stock opened at $234.33 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $259.92. The firm has a market cap of $67.73 billion, a P/E ratio of 48.22, a P/E/G ratio of 1.75 and a beta of 0.43. The company’s 50-day moving average price is $237.52 and its two-hundred day moving average price is $235.10.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Stock Market Sectors: What Are They and How Many Are There?
- Intel: Is Now the Time to Be Brave?
- What is the Nasdaq? Complete Overview with History
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.